Page 1246 - Basic _ Clinical Pharmacology ( PDFDrive )

1232 Index

Oxytocin antagonist, 681, 684t deficiency of, 784 distribution of drugs, 1052–1053
Ozone, 1007t, 1008–1009 on gut, bone, and kidney, 778t dosage and dosage calculations in,
Paravertebral chains, 91 1056–1057, 1057t
P Parcopa, 495 dosage forms and compliance in, 1054
Pacemaker cells, 229f Paricalcitol. See also Vitamin D excretion of drugs, 1053–1054
Paclitaxel, 962t, 963 for bone homeostasis, 775, 777t, 789t metabolism of drugs, 1053
Paget’s disease of bone, 788–789 chronic kidney disease treated with, 785 neonate pharmacodynamics in, 1054
Pain Paritaprevir, 890 placental and fetal drug metabolism in,
kinins in, 307 Parkinsonism, 493–503 1048
treatment of. See Opioid(s), 553 antipsychotics as cause of, 522 Pediculicides, OTC, 1126t
Paliperidone, 515 drug-induced, 503 Pefloxacin, 838
Palivizumab drugs for, 502–503. See also specific drugs Pegademase, 984
description of, 893, 995 acetylcholine-blocking drugs, 501t, Pegatinib, 995, 1065
respiratory syncytial virus treated with, 501–502, 508t Pegfilgrastim, 602–603, 606t
1181t amantadine, 501 Pegloticase, 663
Palonosetron, antiemetic properties of, apomorphine, 501, 508t Pegvisomant, 672, 683t
1104 catechol-O-methyltransferase Pegylated interferon. See also Interferons
Palosuran, 316, 318t. See also Urotensin inhibitors, 500, 508t preparations available, 893t–894t
antagonists dopamine receptor agonists, 497–499, with ribavirin, 80t, 85
Pamidronate 508t Pelvic ganglia, 91
on bone homeostasis, 779f, 779–781 levodopa, 494–497, 508t Pembrolizumab, 975, 992
hypercalcemia treated with, 782 monamine oxidase inhibitors, 495f, Pemetrexed, 957–958, 958t
osteoporosis, bone metastases, and 498f, 499–500, 508t Penbutolol, 162, 164t, 166, 170t, 183.
hypercalcemia treated with, 789t functional circuitry of, 493f See also b-receptor antagonist drugs
Pancreas, endocrine, 747 gene therapy for, 502 Penciclovir
Pancreatic enzyme supplements, neuroprotective therapy for, 502 herpes simplex virus treated with, 865t,
1112–1113, 1116t nonmotor manifestation therapy in, 502 866f, 867
Pancreatic hormones, 747–751 pathogenesis of, 493–494, 495f topical dermatologic, 1074
fundamentals of, 747 surgical procedures for, 502 varicella zoster virus treated with, 865t,
insulin, 747–749. See also Insulin Parkinson’s disease, 127t, 130 866f, 867
Pancreatic insufficiency, exocrine, 1112 Paromomycin (Sulfate), 831–832 Pendred syndrome (PDS), 687
Pancreatic peptide, 747 amebiasis treated with, 929t, 930f, 931 Penicillamine (D-dimethylcysteine)
Pancreatic polypeptide (PP), 315 trypanosomiasis and leishmaniasis chelation uses of, 1030f, 1032
Pancreatin, 1112, 1116t treated with, 932t, 935 Wilson’s disease treated with, 507
Pancrelipase, 1112, 1116t Paroxetine, 540t, 542t, 549t. See also Penicillin(s), 795–801, 812t, 1053
Pancuronium. See also Neuromuscular Selective serotonin reuptake adverse reactions to, 801
blocking drugs inhibitors (SSRIs) chemistry and structure of, 795, 796f
description of, 119 dosing of, 546t classification of, 795–797, 796f
properties of, 478t poisoning with, treating, 1042 antistaphylococcal penicillins, 796,
structure of, 476f, 477f Partial agonists, 5–6, 6f, 24–25, 25f 796f
Panitumumab, 966t, 967–968, 992 Partial pressure, 442–444 extended-spectrum penicillins, 796,
Pantoprazole, 1091–1095. See also proton- Partial seizures, 413–421 796f
pump inhibitors (PPIs) Passive immunization, 1175, 1179, penicillins, 795–797, 796f
Parabens, 901 1180t–1181t, 1181 units and formulation of, 797, 813t
Paracrine factors, 259 Pasteurization, 898t clinical uses of
Paragonimiasis, 944 Patent, drug, 17 benzathine penicillin, 799
Paralytic ileus, 119 Patent ductus arteriosus, 335 extended-spectrum penicillins, 801
Paramethasone, 709t. See also Patient-controlled analgesia (PCA), 564 fundamentals of, 800
Corticosteroids, synthetic Pay to delay, 18 penicillin G, 798
Paraoxon, 116f Pazopanib, 966t, 969 penicillin V, 800
Paraquat, 1013f, 1014 PB1046, 313 procaine penicillin G, 799
Parasympathetic nervous system, 90f, PCSK9 mutations, 631 staphylococcal beta lactamase–resistant
90–91 PD149163, 317t. See also Neurotensin penicillins, 800–801
Parathion, 116f, 122t. See also Organophos- agonists dosing and administration of, 799, 800t
phate cholinesterase inhibitors PDE-5 inhibitors, for erectile dysfunction, mechanism of action of, 797, 797f–799f
Parathyroid hormone (PTH) 200b pharmacokinetics of, 798–799
on bone mineral homeostasis, 774f, Pediatric pharmacology, 1050–1054 preparations available, 813t
774–775 absorption of drugs, 1050, 1052, 1052t resistance to, 797–798